Theravance - THRX Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theravance - THRX

THRX 9.810

+0.4%

Jan 8 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: idos	2/4/2009 11:24:35 AM
	of 74

Three asthma phase IIb studies of the inhaled corticosteroid (ICS) GW685698 ('698), which are part of the Horizon respiratory program, showed statsig improvements in trough FEV1. Theravance, Glaxo asthma drug meets study goals biz.yahoo.com SOUTH SAN FRANCISCO, Calif. (AP) -- Theravance Inc. said Wednesday a midstage study of a developing inhaled asthma treatment improved lung function in three midstage studies. The fluticasone furoate treatment is being developed with partner GlaxoSmithKline. The Phase IIb clinical trials involved 1,800 patients receiving varying doses of once-daily fluticasone furoate. The drug met its goals in all but the lowest, 25-microgram dose. The companies are selecting which doses to move into more advanced studies. The most common side effect seen in the studies were headaches.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next